CN111097029A - 一种用于辅助痛风的保健用品及其制备方法 - Google Patents
一种用于辅助痛风的保健用品及其制备方法 Download PDFInfo
- Publication number
- CN111097029A CN111097029A CN201911402985.XA CN201911402985A CN111097029A CN 111097029 A CN111097029 A CN 111097029A CN 201911402985 A CN201911402985 A CN 201911402985A CN 111097029 A CN111097029 A CN 111097029A
- Authority
- CN
- China
- Prior art keywords
- parts
- gout
- borneol
- hydroxybenzoate
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 201000005569 Gout Diseases 0.000 title claims abstract description 24
- 230000036541 health Effects 0.000 title claims description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 48
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims abstract description 26
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims abstract description 26
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims abstract description 26
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 25
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 24
- 229940116229 borneol Drugs 0.000 claims abstract description 24
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 24
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 24
- 229940043351 ethyl-p-hydroxybenzoate Drugs 0.000 claims abstract description 24
- 239000003814 drug Substances 0.000 claims abstract description 22
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims abstract description 21
- 244000163122 Curcuma domestica Species 0.000 claims abstract description 19
- 235000003392 Curcuma domestica Nutrition 0.000 claims abstract description 19
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 19
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 19
- 235000009411 Rheum rhabarbarum Nutrition 0.000 claims abstract description 19
- 235000003373 curcuma longa Nutrition 0.000 claims abstract description 19
- 235000013976 turmeric Nutrition 0.000 claims abstract description 19
- 241000213006 Angelica dahurica Species 0.000 claims abstract description 18
- 241000972672 Phellodendron Species 0.000 claims abstract description 18
- 235000001855 Portulaca oleracea Nutrition 0.000 claims abstract description 18
- 241000218989 Trichosanthes Species 0.000 claims abstract description 18
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 18
- 235000011477 liquorice Nutrition 0.000 claims abstract description 18
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000000463 material Substances 0.000 claims abstract description 9
- 238000009098 adjuvant therapy Methods 0.000 claims abstract description 7
- 244000234609 Portulaca oleracea Species 0.000 claims abstract 4
- 244000299790 Rheum rhabarbarum Species 0.000 claims abstract 4
- 239000002994 raw material Substances 0.000 claims abstract 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 61
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 38
- 238000003756 stirring Methods 0.000 claims description 30
- 239000000706 filtrate Substances 0.000 claims description 23
- 238000001914 filtration Methods 0.000 claims description 22
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 19
- 229920002125 Sokalan® Polymers 0.000 claims description 19
- 229960001631 carbomer Drugs 0.000 claims description 19
- 239000012153 distilled water Substances 0.000 claims description 18
- 238000002791 soaking Methods 0.000 claims description 16
- 238000001816 cooling Methods 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- 239000011159 matrix material Substances 0.000 claims description 11
- 239000000047 product Substances 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 230000001502 supplementing effect Effects 0.000 claims description 8
- 239000000758 substrate Substances 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 229960005150 glycerol Drugs 0.000 claims description 2
- 230000007794 irritation Effects 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims description 2
- 238000003809 water extraction Methods 0.000 claims description 2
- 208000007514 Herpes zoster Diseases 0.000 claims 1
- 239000008280 blood Substances 0.000 abstract description 11
- 210000004369 blood Anatomy 0.000 abstract description 11
- 208000002193 Pain Diseases 0.000 abstract description 10
- 208000006820 Arthralgia Diseases 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 208000024891 symptom Diseases 0.000 abstract description 3
- 230000002500 effect on skin Effects 0.000 abstract 1
- 239000000499 gel Substances 0.000 description 21
- 241000219061 Rheum Species 0.000 description 15
- 241000219304 Portulacaceae Species 0.000 description 14
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 13
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 13
- 235000011187 glycerol Nutrition 0.000 description 13
- 229940116269 uric acid Drugs 0.000 description 13
- 238000002156 mixing Methods 0.000 description 9
- 238000005303 weighing Methods 0.000 description 9
- 230000001737 promoting effect Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- 235000021355 Stearic acid Nutrition 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 5
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 5
- 239000008117 stearic acid Substances 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- 239000004166 Lanolin Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 229940039717 lanolin Drugs 0.000 description 4
- 235000019388 lanolin Nutrition 0.000 description 4
- 229940057995 liquid paraffin Drugs 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 230000002175 menstrual effect Effects 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- PUSKHXMZPOMNTQ-UHFFFAOYSA-N ethyl 2,1,3-benzoselenadiazole-5-carboxylate Chemical group CCOC(=O)C1=CC=C2N=[Se]=NC2=C1 PUSKHXMZPOMNTQ-UHFFFAOYSA-N 0.000 description 2
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- 241000218158 Clematis Species 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241000972673 Phellodendron amurense Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009924 canning Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000006825 purine synthesis Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000008517 radix Trichosanthis Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/428—Trichosanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种辅助治疗痛风的保健用品及其制备方法，属于保健用品领域。它是由下列重量份的原料药制成：黄柏80‑100份，大黄80‑100份，天花粉80‑100份、姜黄80‑100份、白芷80‑100份、马齿苋80‑100份、甘草50‑70份、丙三醇(甘油)40‑60份、卡波姆(940型)：8‑15份、冰片3‑8份、对羟基苯甲酸乙酯0.8‑1.2份、氮酮8‑12份、三乙醇胺10‑15份。本发明为黄棕色凝胶状，气微，味辛凉，具有清热解毒、祛风止痛，逐瘀通经的作用，用于辅助治疗因痛风导致的关节红、肿、热、痛症状。本发明通过采用皮肤直接涂抹患处方式，对痛风所导致的皮肤等症状有辅助治疗效果，其制备工艺简单且成本低廉。
Description
技术领域
本发明属于保健用品领域。涉及一种辅助治疗痛风的保健用品及其制备方法。
背景技术
从西医角度来看在人体有一种叫嘌呤的物质，当它的代谢发生紊乱后就会引起痛风。嘌呤经过一系列代谢变化，最终形成的产物叫尿酸。尿酸在人体里没有什么生理功能，在正常情况下，体内产生的尿酸2/3由肾脏排出，余下的由大肠排出。体内尿酸是在不断的生成和排泄的，因此它在血液中维持一定的浓度。正常人每100ml血中所含尿酸，男性为6mg以下，女性则不超过5mg。在嘌呤的合成与分解过程中，有多种酶的参与，由于酶的先天性异常或某些尚未明确的因素，代谢发生紊乱，使尿酸的合成增加或排除减少，结果均引起高尿酸血症。当血尿酸浓度过高时，尿酸即以钠盐的形式沉积在关节、软组织、软骨和肾脏中，引起组织的异物炎症反应，成了引起痛风的最终根源。目前西医主要采用镇痛和消炎药物暂时缓解疼痛及口服促进尿酸排泄和抑制尿酸合成的药物。临床上抑制尿酸合成的药物只有别嘌呤醇，而促进尿酸形成的药物有：丙黄舒、痛风利仙等。
从中医病因的角度来看，引起痛风的原因无外乎两大方面，第一个大方面是外因.从外因角度来痛风是由风寒湿热等邪气侵袭人体的经脉，导致经络痹阻，从而诱发的痛风。第二个大的原因是内因。内因主要有三个方面，一是劳逸不当，即劳倦过度导致正气耗伤或者汗出当风，外邪乘虚而入，从而导致经络阻滞，气血运行不畅而成。二是体质亏虚即体质虚弱或者病后气血不足，卫气不固，外邪乘虚而入。三是饮食不当，即吃了容易诱发痛风的食物，从而致病。其临床表现也不一样，风邪偏重的关节疼痛、游走不定；寒邪偏重的，关节疼痛有鼎位，但是疼痛比较厉害；湿邪偏重的，除了疼痛还伴有麻木、重着、肿胀的症状；热邪偏重的，关节红肿灼热疼痛，痛不可忍、痛不可近。痛风初起多实证，痛风日久多虚证或虚实夹杂症。痛风经久不愈会由急性痛风转化为慢性痛风。中医在治疗痛风的原则是以清热利湿、活血通络为法，加之中药中所含的一些生物成分，促进尿酸的排泄。目前治疗痛风的中成药主要有清痹通络酒和复方伸筋胶囊等。
本发明是在西医或者中医治疗痛风基础上以皮肤涂抹方式辅助治疗患者使之减少痛苦的一款保健用品，该产品易于皮肤吸收、起效快，使用方便、安全无副作用并且制作工艺简单成本低廉。
发明内容
本发明的解决方案是在临床治疗痛风基础上以减轻患者痛苦为基础原则又参考现代药理研究，其中黄柏具有清热燥湿、泻火除蒸、解毒疗疮等功效。大黄具有清热泻火、凉血解毒、逐瘀通经，利湿退黄等功效。天花粉具有清热泻火、生津止渴、消肿排脓等功效。姜黄具有破血行气，通经止痛等功效。白芷具有解表散寒、祛风止痛、宜通鼻窍、燥湿止带，消肿排脓等功效。马齿苋具有清热解毒、凉血止血等功效。甘草具有清热解毒、调和诸药等功效。冰片具有清热解毒、防腐生肌的功效，以上八味按中医理论组方，最终达到辅助治疗痛风的目的。
本发明药物组分的用量也是经过发明人进行大量摸索总结得出的，各组分用量为在下述重量范围内都具有较好疗效：
黄柏80-100份，大黄80-100份，天花粉80-100份、姜黄80-100份、白芷80-100份、马齿苋80-100份、甘草50-70份、冰片3-8份、丙三醇(甘油)40-60份、卡波姆(940型)：8-15份、对羟基苯甲酸乙酯0.8-1.2份、氮酮8-12份、三乙醇胺10-15份。
优选为：
黄柏90份，大黄90份，天花粉90份、姜黄90份、白芷90份、马齿苋90份、甘草60份、冰片5份、丙三醇(甘油)50份、卡波姆(940型)：12份、对羟基苯甲酸乙酯1份、氮酮10份、三乙醇胺14份。
本发明保健用品采用中药制剂的常规提取方法制备成的外用凝胶。
3、权利要求1或2所述物料的制备方法，按下列步骤进行操作：
(1)取处方量的黄柏、大黄、天花粉、姜黄、白芷、马齿苋、甘草加12倍量水浸泡30分钟后提取2次，每次各1小时，合并提取液滤过，滤液浓缩至相对密度1.05-1.10，冷却至室温加乙醇使含醇量达60％后静置24小时后，滤过，滤液浓缩至相对密度为1.10-1.20的清膏，备用。
(2)基质的制备：取处方量的卡波姆(940型)用660份水浸泡24小时即可。
(3)取制备完毕的(2)加入(1)制得提取液搅拌均匀后依次加入丙三醇(甘油)、冰片、对羟基苯甲酸乙酯、氮酮搅拌直至均匀后加入三乙醇胺后加水至1000份后继续搅拌均匀至凝胶状即可。
备注：冰片、对羟基苯甲酸乙酯分别用25ml乙醇溶解后加入。
4、根据权利3所述的制备方法，其特征在于：步骤(1)黄柏、大黄、天花粉、姜黄、白芷、马齿苋、甘草使用水提取及醇沉的操作方法，即能达到对药材有效成分提取的目的又能去除无活性的杂质。步骤(2)卡波姆制作的基质具有保护肌肤，减少刺激等特性。(3)通过将提取液与基质混合均匀再加入及其它物质再次混合均匀后最后加入三乙醇胺搅拌均匀使成凝胶。
本发明为棕黄色凝胶状，气微，味辛凉，每1ml相当于0.6g生药，临床用量每日涂抹患处三次。每只装30g。
本发明保健用品具有清热解毒、祛风止痛，逐瘀通经的作用。
具体实施方式：
以下通过实施例来进一步说明本发明保健用品的制备方法。
实施例1：本发明凝胶剂的制备
1)黄柏80份、大黄80份、天花粉80份、姜黄80份、白芷80份、马齿苋80份、甘草50份，加12倍量水浸泡30分钟后提取2次，每次各1小时，合并提取液滤过，滤液浓缩至相对密度1.05-1.10后冷却至室温后加乙醇使含醇量达60％静置24小时后，滤过，滤液浓缩至相对密度1.05-1.10的清膏，备用。
2)基质的配制：取卡波姆(940型)8份，加蒸馏水580份浸泡24小时使之充分溶胀后备用。
3)取1)加入2)中搅拌均匀后依次加入丙三醇(甘油)50份、冰片3份、对羟基苯甲酸乙酯0.8份、氮酮8份搅拌直至均匀再加入三乙醇胺10份后用蒸馏水补至1000份继续搅拌均匀至凝胶状即可。
备注：冰片、对羟基苯甲酸乙酯分别用25份乙醇充分溶解后加入。
实施例2：本发明凝胶剂的制备
1)准确称黄柏85份、大黄85份、天花粉85份、姜黄85份、白芷85份、马齿苋85份、甘草55份加12倍量水浸泡30分钟后提取2次，每次各1小时，合并提取液滤过，滤液浓缩至相对密度1.05-1.10后冷却至室温后加乙醇使含醇量达60％静置24小时后，滤过，滤液浓缩至相对密度1.08-1.12的清膏，备用。
2)基质的配制：取卡波姆(940型)12份，加蒸馏水600份浸泡24小时使之充分溶胀后备用。
3)取1)加入2)中搅拌均匀后依次加入丙三醇(甘油)50份、冰片5份、对羟基苯甲酸乙酯1份、氮酮8份搅拌直至均匀再加入三乙醇胺11份后用蒸馏水补至1000份继续搅拌均匀至凝胶状即可。
备注：冰片、对羟基苯甲酸乙酯分别用25份乙醇充分溶解后加入。
实施例3：本发明凝胶剂的制备
1)准确称黄柏90份、大黄90份、天花粉90份、姜黄90份、白芷90份、马齿苋90份、甘草60份加12倍量水浸泡30分钟后提取2次，每次各1小时，合并提取液滤过，滤液浓缩至相对密度1.05-1.10后冷却至室温后加乙醇使含醇量达60％静置24小时后，滤过，滤液浓缩至相对密度1.10-1.15的清膏，备用。
2)基质的配制：取卡波姆(940型)12份，加蒸馏水620份浸泡24小时使之充分溶胀后备用。
3)取1)加入2)中搅拌均匀后依次加入丙三醇(甘油)50份、冰片5份、对羟基苯甲酸乙酯1.2份、氮酮10份搅拌直至均匀再加入三乙醇胺12份后用蒸馏水补至1000份继续搅拌均匀至凝胶状即可。
备注：冰片、对羟基苯甲酸乙酯分别用25份乙醇充分溶解后加入。
实施例4：本发明凝胶剂的制备
1)准确称黄柏90份、大黄90份、天花粉90份、姜黄90份、白芷90份、马齿苋90份、甘草60份加12倍量水浸泡30分钟后提取2次，每次各1小时，合并提取液滤过，滤液浓缩至相对密度1.05-1.10后冷却至室温后加乙醇使含醇量达60％静置24小时后，滤过，滤液浓缩至相对密度1.10-1.20的清膏，备用。
2)基质的配制：取卡波姆(940型)13份，加蒸馏水640份浸泡24小时使之充分溶胀后备用。
3)取1)加入2)中搅拌均匀后依次加入丙三醇(甘油)50份、冰片5份、对羟基苯甲酸乙酯1.2份、氮酮10份搅拌直至均匀再加入三乙醇胺14份后用蒸馏水补至1000份继续搅拌均匀至凝胶状即可。
备注：冰片、对羟基苯甲酸乙酯分别用25份乙醇充分溶解后加入。
实施例5：本发明凝胶剂的制备
1)准确称黄柏90份、大黄90份、天花粉90份、姜黄90份、白芷90份、马齿苋90份、甘草60份加12倍量水浸泡30分钟后提取2次，每次各1小时，合并提取液滤过，滤液浓缩至相对密度1.05-1.10后冷却至室温后加乙醇使含醇量达60％静置24小时后，滤过，滤液浓缩至相对密度1.10-1.20的清膏，备用。
2)基质的配制：取卡波姆(940型)14份，加蒸馏水660份浸泡24小时使之充分溶胀后备用。
3)取1)加入2)中搅拌均匀后依次加入丙三醇(甘油)50份、冰片5份、对羟基苯甲酸乙酯1.2份、氮酮10份搅拌直至均匀再加入三乙醇胺14份后用蒸馏水补至1000份继续搅拌均匀至凝胶状即可。
备注：冰片、对羟基苯甲酸乙酯分别用25份乙醇充分溶解后加入。
实施例6：本发明凝胶剂的制备
准确称黄柏90份、大黄90份、天花粉90份、姜黄90份、白芷90份、马齿苋90份、甘草60份加12倍量水浸泡30分钟后提取2次，每次各1小时，合并提取液滤过，滤液浓缩至相对密度1.05-1.10后冷却至室温后加乙醇使含醇量达60％静置24小时后，滤过，滤液浓缩至相对密度1.10-1.20的清膏，备用。
2)基质的配制：取卡波姆(940型)12份，加蒸馏水660份浸泡24小时使之充分溶胀后备用。
3)取1)加入2)中搅拌均匀后依次加入丙三醇(甘油)50份、冰片5份、对羟基苯甲酸乙酯1.0份、氮酮10份搅拌直至均匀再加入三乙醇胺14份后用蒸馏水补至1000份继续搅拌均匀至凝胶状即可。
备注：冰片、对羟基苯甲酸乙酯分别用25份乙醇充分溶解后加入。
实施例7：本发明凝胶剂的制备
1)准确称黄柏100份、大黄100份、天花粉100份、姜黄100份、白芷100份、马齿苋100份、甘草70份加12倍量水浸泡30分钟后提取2次，每次各1小时，合并提取液滤过，滤液浓缩至相对密度1.05-1.10后冷却至室温后加乙醇使含醇量达60％静置24小时后，滤过，滤液浓缩至相对密度1.10-1.20的清膏，备用。
2)基质的配制：取卡波姆(940型)17份，加蒸馏水680份浸泡24小时使之充分溶胀后备用。
3)取1)加入2)中搅拌均匀后依次加入丙三醇(甘油)50份、冰片5份、对羟基苯甲酸乙酯1.2份、氮酮12份搅拌直至均匀再加入三乙醇胺16份后，用蒸馏水补至1000份继续搅拌均匀至凝胶状即可。
实施例8：本发明乳剂的制备
1)准确称黄柏90份、大黄90份、天花粉90份、姜黄90份、白芷90份、马齿苋90份、甘草60份加12倍量水浸泡30分钟后提取2次，每次各1小时，合并提取液滤过，滤液浓缩至相对密度1.05-1.10后冷却至室温后加乙醇使含醇量达60％静置24小时后，滤过，滤液浓缩至相对密度1.10-1.20的清膏，备用。
2)基质的配制：取硬脂酸120g、单硬脂酸甘油酯35g、液体石蜡60g、凡士林10g、羊毛脂50g置容器内，水浴热至熔化，继续加热至70℃-80℃后备用。
3)另取三乙醇胺、尼泊金乙酯、上述提取药液及蒸馏水，加热至70℃-80℃，缓缓倒入硬脂酸等油相中，边加边搅拌，直至乳化完全，放冷后加入冰片搅拌均匀后分装。
实施例9：本发明软膏剂的制备
1)准确称黄柏90份、大黄90份、天花粉90份、姜黄90份、白芷90份、马齿苋90份、甘草60份加12倍量水浸泡30分钟后提取2次，每次各1小时，合并提取液滤过，滤液浓缩至相对密度1.05-1.10后冷却至室温后加乙醇使含醇量达60％静置24小时后，滤过，滤液浓缩至相对密度1.10-1.20的清膏，备用。
2)油相的配制：取硬脂酸120g、液体石蜡60g、羊毛脂50g置容器内，水浴热至熔化得油相，70℃-80℃保温备用。
3)水相的配制：取三乙醇胺、尼泊金乙酯、上述提取药液及蒸馏水，加热至70℃-80℃得水相，将水相缓缓加入油相中，按同一方向不断搅拌至细腻的膏状。
实施例10：本发明气雾剂的制备
1)准确称黄柏90份、大黄90份、天花粉90份、姜黄90份、白芷90份、马齿苋90份、甘草60份加12倍量水浸泡30分钟后提取2次，每次各1小时，合并提取液滤过，滤液浓缩至相对密度1.05-1.10后冷却至室温后加乙醇使含醇量达60％静置24小时后，滤过，减压回收乙醇，制成每1ml含生药0.6g喷雾液，罐装于30ml安瓶内，灭菌即得。
备注：冰片、对羟基苯甲酸乙酯分别用25份乙醇充分溶解后加入。
技术总结：本发明涉及一种辅助治疗痛风凝胶的制备方法，在提取工艺上采用水提醇沉的提取方法即能达到对药材有效成分提取的目的又能去除无活性的杂质，再加入凝胶剂基质卡波姆、保湿剂甘油、皮肤渗透促进剂氮酮、防腐剂对羟基苯甲酸乙酯、PH调节剂三乙醇胺，通过调整组分用量及提取工艺的试验最终确定了保健用品凝胶剂、乳剂、软膏剂及喷雾剂可行的制备方法且制备方法简单易操作且成本较低。
Claims (4)
1.一种用于辅助治疗痛风的保健用品，其特征在于它是由下列重量份的原料药制成：
黄柏80-100份，大黄80-100份，天花粉80-100份、姜黄80-100份、白芷80-100份、马齿苋80-100份、甘草50-70份、丙三醇(甘油)40-60份、卡波姆(940型)：8-15份、冰片3-8份、对羟基苯甲酸乙酯0.8-1.2份、氮酮8-12份、三乙醇胺10-15份。
2.根据权利要求1所述的辅助治疗带状疱疹的保健用品，其特征在于各个原料药的用量为：黄柏90份，大黄90份，天花粉90份、姜黄90份、白芷90份、马齿苋90份、甘草60份、丙三醇(甘油)50份、卡波姆(940型)12份、冰片5份、对羟基苯甲酸乙酯1份、氮酮10份、三乙醇胺14份。
3.权利要求1或2所述物料的制备方法，按下列步骤进行操作：
(1)取处方量的黄柏、大黄、天花粉、姜黄、白芷、马齿苋、甘草加12倍量水浸泡30分钟后提取2次，每次各1小时，合并提取液滤过，滤液浓缩至相对密度1.05-1.10，冷却至室温加乙醇使含醇量达60％后静置24小时后，滤过，滤液浓缩至相对密度为1.10-1.20的清膏，备用。
(2)基质的制备：取处方量的卡波姆(940型)用660份蒸馏水水浸泡24小时使之充分溶胀后备用。
(3)取制备完毕的(2)加入(1)制得提取液搅拌均匀后依次加入丙三醇(甘油)、冰片、对羟基苯甲酸乙酯、氮酮搅拌直至均匀再加入三乙醇胺用蒸馏水补至1000份后继续搅拌均匀至凝胶状即可。
备注：冰片、对羟基苯甲酸乙酯分别用25ml乙醇充分溶解后加入。
4.根据权利3所述的制备方法，其特征在于：步骤(1)黄柏、大黄、天花粉、姜黄、白芷、马齿苋、甘草使用水提取及醇沉的操作方法，充分达到对药材有效成分提取的目的又能去除无活性的杂质。步骤(2)卡波姆制作的基质具有保护肌肤，减少刺激等特性。(3)通过将提取液与基质等物质混合均匀最后加入三乙醇胺调节PH值使成凝胶。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911402985.XA CN111097029A (zh) | 2019-12-31 | 2019-12-31 | 一种用于辅助痛风的保健用品及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911402985.XA CN111097029A (zh) | 2019-12-31 | 2019-12-31 | 一种用于辅助痛风的保健用品及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111097029A true CN111097029A (zh) | 2020-05-05 |
Family
ID=70425076
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911402985.XA Pending CN111097029A (zh) | 2019-12-31 | 2019-12-31 | 一种用于辅助痛风的保健用品及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111097029A (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112057587A (zh) * | 2020-10-14 | 2020-12-11 | 深圳市福田区妇幼保健院 | 一种痛风用中药组合物及其制备方法、外用药和应用 |
| CN115671234A (zh) * | 2022-11-01 | 2023-02-03 | 贵州省黔南布依族苗族自治州中医医院 | 一种治疗痛风的药物组合物及其制备方法与应用 |
-
2019
- 2019-12-31 CN CN201911402985.XA patent/CN111097029A/zh active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112057587A (zh) * | 2020-10-14 | 2020-12-11 | 深圳市福田区妇幼保健院 | 一种痛风用中药组合物及其制备方法、外用药和应用 |
| CN115671234A (zh) * | 2022-11-01 | 2023-02-03 | 贵州省黔南布依族苗族自治州中医医院 | 一种治疗痛风的药物组合物及其制备方法与应用 |
| CN115671234B (zh) * | 2022-11-01 | 2024-02-02 | 贵州省黔南布依族苗族自治州中医医院 | 一种治疗痛风的药物组合物及其制备方法与应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105878322B (zh) | 一种结晶酶解法制备的葵花盘提取物及其制备方法 | |
| CN103750107B (zh) | 一种具有降糖功能的保健品 | |
| CN105920067A (zh) | 一种含多糖、黄酮和生物碱的葵花盘提取物及其制备方法 | |
| CN111686147A (zh) | 一种杜仲提取物及其在治疗骨质疏松中的应用 | |
| CN111097029A (zh) | 一种用于辅助痛风的保健用品及其制备方法 | |
| CN111053818A (zh) | 一种用于辅助治疗皮肤瘙痒的保健用品及其制备方法 | |
| AU2020103082A4 (en) | Traditional chinese medicine composition, traditional chinese medicine compound preparation for treating gout and preparation method thereof | |
| CN104888058B (zh) | 一种抑菌、消炎外用制剂及其制备方法 | |
| CN103007000A (zh) | 一种治疗烧烫伤、创疡的新药及制备方法 | |
| JPH05186360A (ja) | アレルギー性疾患用の治療剤及びエゾウコギ抽出物の製造方法 | |
| CN108164524A (zh) | 一种黄藤素及提取方法、黄藤素胶囊及制备方法 | |
| WO2019077400A1 (zh) | 一种治疗风湿骨痛的内服三七药酒的制备工艺 | |
| CN110025705A (zh) | 一种治疗特应性皮炎的中药组合物及其制备方法和应用 | |
| CN101152223B (zh) | 杨树叶酚类提取物在制备治疗心律失常的药物中的应用 | |
| CN106963912B (zh) | 一种治疗湿疹的降香复方组合物及其制备方法 | |
| CN110051719B (zh) | 一种透骨草和侧柏叶混合提取物及其提取工艺与应用 | |
| CN101249173B (zh) | 治疗痛风的中药制剂及其制备方法 | |
| CN1233343C (zh) | 一种治疗创疡疾病的中药组合物 | |
| CN106880654B (zh) | 竹节参提取物在制备治疗鼻炎药物中的应用及组合物 | |
| CN105902867B (zh) | 一种降三高的植物药组合物及其制备方法 | |
| CN101234139A (zh) | 一种治疗感冒的中成药及其制备方法 | |
| WO2019127036A1 (zh) | 预防和治疗结石、高血尿酸、痛风症及其并发症的中药组合物、其制备方法及其应用 | |
| CN116549522B (zh) | 一种中药组合物在痛风中的用途 | |
| CN107837315A (zh) | 一种治疗鹅掌风的中药组合物及其制备方法 | |
| CN111053809A (zh) | 一种用于辅助治疗带状疱疹的保健用品及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200505 |